ANALYSISModerna and Merck's personalized vaccine slowed melanoma's return when added to Keytruda. It is the first mRNA cancer vaccine to succeed at scale — and the first real test of a decade-old idea.
3 min read
EXPLAINERSPF measures how much ultraviolet exposure it takes to burn, not how long you can stay outside. The randomised cancer-prevention evidence rests largely on 1,621 adults followed for more than a decade.
5 min read
THE DRUG DOCKETThe CHMP's June meeting recommended pulling avacopan from the EU market on data-integrity grounds, refused three cell and biological therapies, and reversed itself on a Rett syndrome drug it had earlier rejected.
4 min read
WHAT THE STUDY ACTUALLY SAYSA linked-registry cohort of New South Wales residents from 2001 to 2018 finds cancer risk in people with intellectual disability inverts with age — higher when young, lower after 50.
4 min read
EXPLAINERIntegrated risk scores combine polygenic data with conventional risk factors. A readiness review lists what would have to exist first — and separately, 36% of older Australians had no skin check at all last year.
4 min read
WHAT THE STUDY ACTUALLY SAYSFifty-five per cent of surveyed cricketers over 70 reported a basal cell carcinoma. A 29% response rate and self-reported diagnoses mean the number cannot be read as a rate — which is the finding.
4 min read
This page indexes this newspaper’s reporting on Melanoma. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.